NASDAQ:GRCE Grace Therapeutics Q2 2026 Earnings Report $2.44 +0.03 (+1.24%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Grace Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.12Beat/MissMissed by -$0.03One Year Ago EPSN/AGrace Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGrace Therapeutics Announcement DetailsQuarterQ2 2026Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETUpcoming EarningsGrace Therapeutics' Q1 2027 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2027 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Grace Therapeutics Earnings HeadlinesGrace Therapeutics Inc Ordinary Shares GRCEJune 24, 2026 | morningstar.comMGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateJune 18, 2026 | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 17 at 1:00 AM | Investors Alley (Ad)GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 8, 2026 | prnewswire.comGrace Therapeutics VP of Clinical Operations Departs RoleJune 5, 2026 | tipranks.comSee More Grace Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email. Email Address About Grace TherapeuticsGrace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.View Grace Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetJ.B. Hunt Stock Could Reach $340 as Trucking Capacity ShrinksPalantir's Wild Ride: Inside the Stock Wall Street Can't Agree OnRevving Up Returns: Big Banks Race Through the Rate Plateau Upcoming Earnings HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
